RedHill Biopharma Has Received A Notice Of Allowance For Its U.S. Patent Application 17/900,235 titled "BIOMARKERS OF CORONAVIRUS PNEUMONIA (FOR TREATING CORONAVIRUS INFECTION OR PREVENTING DISEASES CAUSED BY CORONAVIRUS INFECTION)"
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma has received a Notice of Allowance for its U.S. Patent Application 17/900,235, titled 'BIOMARKERS OF CORONAVIRUS PNEUMONIA (FOR TREATING CORONAVIRUS INFECTION OR PREVENTING DISEASES CAUSED BY CORONAVIRUS INFECTION)'.
June 18, 2024 | 7:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RedHill Biopharma has received a Notice of Allowance for its U.S. Patent Application on biomarkers for treating and preventing coronavirus infections.
The Notice of Allowance for the patent application is a significant milestone for RedHill Biopharma, potentially enhancing its intellectual property portfolio and providing a competitive edge in the treatment and prevention of coronavirus infections. This development is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100